📊 CAPR Key Takeaways
Investment Thesis
Capricor Therapeutics is a pre-revenue biotech company burning significant cash with negative operating income of $108.1M and negative free cash flow of $72.7M, indicating no viable commercial products generating sales. While the company maintains a strong cash position of $287.8M and minimal debt, at current burn rates the runway provides approximately 4 years before depletion, making near-term capital requirements critical.
CAPR Strengths
- Substantial cash reserves of $287.8M provide runway for continued R&D
- Minimal debt burden with zero long-term debt and low leverage ratio
- Excellent liquidity position with 9.01x current ratio
- 11 Form 4 insider filings indicate recent management activity
CAPR Risks
- Zero revenue with no commercial products indicates pre-clinical or early-stage pipeline
- Operating losses of $108.1M annually with negative $72.7M free cash flow indicates unsustainable burn rate
- Cash runway approximately 4 years at current burn rate; will require financing or revenue generation
- Negative ROE of -34.4% and ROA of -29.5% demonstrate value destruction from operations
- Pharmaceutical sector risk including regulatory, clinical trial, and development failures
Key Metrics to Watch
- Quarterly cash burn rate and remaining runway
- Progress of clinical pipeline and regulatory milestones
- Revenue generation timeline and commercial viability of candidates
- Capital raises and dilution impact
- Operating cash flow trend and cost management
CAPR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 9.01x current ratio provides a solid financial cushion.
CAPR Profitability Ratios
CAPR vs Healthcare Sector
How CAPRICOR THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CAPR Balance Sheet & Liquidity
CAPR 5-Year Financial Trend
5-Year Trend Summary: CAPRICOR THERAPEUTICS, INC.'s revenue has grown significantly by 7,078% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.15 indicates the company is currently unprofitable.
CAPR Growth Metrics (YoY)
CAPR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.3M | -$9.8M | $-0.38 |
| Q2 2025 | $4.0M | -$9.8M | $-0.35 |
| Q1 2025 | $4.9M | -$9.8M | $-0.31 |
| Q3 2024 | $2.3M | -$6.4M | $-0.25 |
| Q2 2024 | $3.9M | -$7.4M | $-0.29 |
| Q1 2024 | $3.0M | -$7.8M | $-0.31 |
| Q3 2023 | $1.6M | -$6.4M | $-0.25 |
| Q2 2023 | $3.9M | -$7.1M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CAPR Capital Allocation
CAPR SEC Filings
Access official SEC EDGAR filings for CAPRICOR THERAPEUTICS, INC. (CIK: 0001133869)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CAPR
What is the AI rating for CAPR?
CAPRICOR THERAPEUTICS, INC. (CAPR) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CAPR's key strengths?
Substantial cash reserves of $287.8M provide runway for continued R&D. Minimal debt burden with zero long-term debt and low leverage ratio.
What are the risks of investing in CAPR?
Zero revenue with no commercial products indicates pre-clinical or early-stage pipeline. Operating losses of $108.1M annually with negative $72.7M free cash flow indicates unsustainable burn rate.
What is CAPR's revenue and growth?
CAPRICOR THERAPEUTICS, INC. reported revenue of $0.0.
Does CAPR pay dividends?
CAPRICOR THERAPEUTICS, INC. does not currently pay dividends.
Where can I find CAPR SEC filings?
Official SEC filings for CAPRICOR THERAPEUTICS, INC. (CIK: 0001133869) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CAPR's EPS?
CAPRICOR THERAPEUTICS, INC. has a diluted EPS of $-2.26.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.